Cantor Fitzgerald analyst Sarah James downgraded Health Catalyst (HCAT) to Neutral from Overweight with a price target of $4, down from $9. The firm cites the company’s worsening revenue outlook amid multi-year headwinds for the downgrade. Cantor believes the macro environment is too difficult to support growth at Health Catalyst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT: